Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes

Journal of Proteomics

Volumn 108, Issue , 2014, Pages 198-208

  Carnielli, Juliana B T ^a   de Andrade, Hélida M ^b   Pires, Simone F ^b   Chapeaurouge, Alexander D ^c   Perales, Jonas ^c   Monti Rocha, Renata ^a   Carvalho, Sílvio F G ^d   Ribeiro, Leonardo P ^a   Dietze, Reynaldo ^a   Figueiredo, Suely G ^a   Lemos, Elenice M ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

Author keywords

2D DIGE; L. infantum chagasi; Miltefosine resistance; MS MS; Proteome

Indexed keywords

2,4 DIHYDROXYHEPT 2 ENE 1,7 DIOIC ACID ALDOLASE; ACTIN; ALCOHOL DEHYDROGENASE; CHAPERONIN; CHAPERONIN 60; METHIONINE ADENOSYLTRANSFERASE; MILTEFOSINE; NITRILASE; PEROXIREDOXIN; PROTEIN; PROTEOME; RNA HELICASE; SPERMIDINE SYNTHASE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; PHOSPHORYLCHOLINE; PROTOZOAL PROTEIN;

APOPTOSIS; ARTICLE; HUMAN; IMAGE ANALYSIS; LEISHMANIA CHAGASI; NONHUMAN; OXIDATION REDUCTION REACTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; STRESS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VISCERAL LEISHMANIASIS; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BRAZIL; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; ISOLATION AND PURIFICATION; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; METABOLISM;

ANTIPROTOZOAL AGENTS; BRAZIL; DRUG RESISTANCE; FEMALE; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; PROTOZOAN PROTEINS;

EID: 84902474838     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.05.010     Document Type: Article

References (53)

1. Pearson R.D., Sousa A.Q. Clinical spectrum of Leishmaniasis. Clin Infect Dis 1996, 22:1-13.
2. Engel J. Miltefosine, the story of a successful partnership: disease endemic country - TDR - pharmaceutical industry (Zentaris). TDR News 2002, 68:5.
3. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002, 347:1739-1746.
4. Bhattacharya S.K., Sinha P.K., Sundar S., Thakur C.P., Jha T.K., Pandey K., et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007, 196:591-598.
5. Sundar S., Singh A., Rai M., Prajapati V.K., Singh A.K., Ostyn B., et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012, 55:543-550.
6. Perez-Victoria F.J., Castanys S., Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003, 47:2397-2403.
7. Perez-Victoria F.J., Gamarro F., Ouellette M., Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003, 278:49965-49971.
8. Perez-Victoria F.J., Sanchez-Canete M.P., Castanys S., Gamarro F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 2006, 281:23766-23775.
9. Sanchez-Canete M.P., Carvalho L., Perez-Victoria F.J., Gamarro F., Castanys S. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 2009, 53:1305-1313.
10. Perez-Victoria J.M., Perez-Victoria F.J., Parodi-Talice A., Jimenez I.A., Ravelo A.G., Castanys S., et al. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 2001, 45:2468-2474.
11. Rakotomanga M., Saint-Pierre-Chazalet M., Loiseau P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob Agents Chemother 2005, 49:2677-2686.
12. Vergnes B., Gourbal B., Girard I., Sundar S., Drummelsmith J., Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 2007, 6:88-101.
13. Paris C., Loiseau P.M., Bories C., Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004, 48:852-859.
14. Volpini A.C., Passos V.M., Oliveira G.C., Romanha A.J. PCR-RFLP to identify Leishmania (Viannia) braziliensis and L. (Leishmania) amazonensis causing American cutaneous leishmaniasis. Acta Trop 2004, 90:31-37.
15. Sesana A.M., Monti-Rocha R., Vinhas S.A., Morais C.G., Dietze R., Lemos E.M. In vitro activity of amphotericin B cochleates against Leishmania chagasi. Mem Inst Oswaldo Cruz 2011, 106:251-253.
16. Neuhoff V., Arold N., Taube D., Ehrhardt W. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988, 9:255-262.
17. Vergote D., Bouchut A., Sautiere P.E., Roger E., Galinier R., Rognon A., et al. Characterisation of proteins differentially present in the plasma of Biomphalaria glabrata susceptible or resistant to Echinostoma caproni. Int J Parasitol 2005, 35:215-224.
18. Sundar S., Gupta L.B., Makharia M.K., Singh M.K., Voss A., Rosenkaimer F., et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999, 93:589-597.
19. Sundar S., Rosenkaimer F., Makharia M.K., Goyal A.K., Mandal A.K., Voss A., et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998, 352:1821-1823.
20. Biyani N., Singh A.K., Mandal S., Chawla B., Madhubala R. Differential expression of proteins in antimony-susceptible and -resistant isolates of Leishmania donovani. Mol Biochem Parasitol 2011, 179:91-99.
21. Daneshvar H., Wyllie S., Phillips S., Hagan P., Burchmore R. Comparative proteomics profiling of a gentamicin-attenuated Leishmania infantum cell line identifies key changes in parasite thiol-redox metabolism. J Proteomics 2012, 75:1463-1471.
22. Drummelsmith J., Brochu V., Girard I., Messier N., Ouellette M. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol Cell Proteomics 2003, 2:146-155.
23. Drummelsmith J., Girard I., Trudel N., Ouellette M. Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance. J Biol Chem 2004, 279:33273-33280.
24. Walker J., Gongora R., Vasquez J.J., Drummelsmith J., Burchmore R., Roy G., et al. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol 2012, 183:166-176.
25. Costa M.M., Andrade H.M., Bartholomeu D.C., Freitas L.M., Pires S.F., Chapeaurouge A.D., et al. Analysis of Leishmania chagasi by 2-D difference gel electrophoresis (2-D DIGE) and immunoproteomic: identification of novel candidate antigens for diagnostic tests and vaccine. J Proteome Res 2011, 10:2172-2184.
26. da Fonseca Pires S., Fialho L.C., Silva S.O., Melo M.N., de Souza C.C., Tafuri W.L., et al. Identification of virulence factors in Leishmania infantum strains by a proteomic approach. J Proteome Res 2014, 13:1860-1872.
27. Beere H.M. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004, 117:2641-2651.
28. Folgueira C., Requena J.M. A postgenomic view of the heat shock proteins in kinetoplastids. FEMS Microbiol Rev 2007, 31:359-377.
29. Matrangolo F.S., Liarte D.B., Andrade L.C., de Melo M.F., Andrade J.M., Ferreira R.F., et al. Comparative proteomic analysis of antimony-resistant and -susceptible Leishmania braziliensis and Leishmania infantum chagasi lines. Mol Biochem Parasitol 2013, 190:63-75.
30. Hubel A., Clos J. The genomic organization of the HSP83 gene locus is conserved in three Leishmania species. Exp Parasitol 1996, 82:225-228.
31. Hombach A., Ommen G., Chrobak M., Clos J. The Hsp90-Sti1 interaction is critical for Leishmania donovani proliferation in both life cycle stages. Cell Microbiol 2012, 15(4):585-600.
32. Lassle M., Blatch G.L., Kundra V., Takatori T., Zetter B.R. Stress-inducible, murine protein mSTI1. Characterization of binding domains for heat shock proteins and in vitro phosphorylation by different kinases. J Biol Chem 1997, 272:1876-1884.
33. Verma N.K., Singh G., Dey C.S. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp Parasitol 2007, 116:1-13.
34. Verma N.K., Dey C.S. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004, 48:3010-3015.
35. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A 2000, 97:8841-8848.
36. Droge W. The plasma redox state and ageing. Ageing Res Rev 2002, 1:257-278.
37. Wood Z.A., Poole L.B., Karplus P.A. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003, 300:650-653.
38. Hofmann B., Hecht H.J., Flohe L. Peroxiredoxins. Biol Chem 2002, 383:347-364.
39. Wilkinson S.R., Temperton N.J., Mondragon A., Kelly J.M. Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi. J Biol Chem 2000, 275:8220-8225.
40. Harder S., Bente M., Isermann K., Bruchhaus I. Expression of a mitochondrial peroxiredoxin prevents programmed cell death in Leishmania donovani. Eukaryot Cell 2006, 5:861-870.
41. Das M., Saudagar P., Sundar S., Dubey V.K. Miltefosine unresponsive Leishmania donovani has better ability of resist reactive oxygen species. FEBS J 2013, 280(19):4807-4815.
42. Reid M.F., Fewson C.A. Molecular characterization of microbial alcohol dehydrogenases. Crit Rev Microbiol 1994, 20:13-56.
43. Gomes R.A., Sousa Silva M., Vicente Miranda H., Ferreira A.E., Cordeiro C.A., Freire A.P. Protein glycation in Saccharomyces cerevisiae. Argpyrimidine formation and methylglyoxal catabolism. FEBS J 2005, 272:4521-4531.
44. Vickers T.J., Wyllie S., Fairlamb A.H. Leishmania major elongation factor 1B complex has trypanothione S-transferase and peroxidase activity. J Biol Chem 2004, 279:49003-49009.
45. Vickers T.J., Greig N., Fairlamb A.H. A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major. Proc Natl Acad Sci U S A 2004, 101:13186-13191.
46. Colotti G., Ilari A. Polyamine metabolism in Leishmania: from arginine to trypanothione. Amino Acids 2011, 40:269-285.
47. Kumar A., Sisodia B., Misra P., Sundar S., Shasany A.K., Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol 2010, 70:609-617.
48. Zhang X., Moye-Rowley W.S. Saccharomyces cerevisiae multidrug resistance gene expression inversely correlates with the status of the F(0) component of the mitochondrial ATPase. J Biol Chem 2001, 276:47844-47852.
49. Wyllie S., Vickers T.J., Fairlamb A.H. Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob Agents Chemother 2008, 52:1359-1365.
50. El Fadili K., Drummelsmith J., Roy G., Jardim A., Ouellette M. Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen. Exp Parasitol 2009, 123:51-57.
51. Chawla B., Jhingran A., Panigrahi A., Stuart K.D., Madhubala R. Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani. PLoS One 2011, 6:e26660.
52. Sharma S., Singh G., Chavan H.D., Dey C.S. Proteomic analysis of wild type and arsenite-resistant Leishmania donovani. Exp Parasitol 2009, 123:369-376.
53. Moreira W., Leprohon P., Ouellette M. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis 2011, 2:e201.